A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.

Also called NCT01242202

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 113 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01242202
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01242202. Allocation not applicable; no masking; primary purpose treatment. Start 2010-10-21 (actual); primary completion 2012-05-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
ipragliflozin
Intervention (Drug)
alpha glucosidase inhibitor
Lead sponsor
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct01242202
Content hash
95d357a4352f50f18172af6d73943ea872f92a83150a1859a5496586d18a8d90